

Jack A Schalken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1568922/publications.pdf>

Version: 2024-02-01

459
papers

22,556
citations

7096

78
h-index

12272

133
g-index

476
all docs

476
docs citations

476
times ranked

19937
citing authors

#	ARTICLE	IF	CITATIONS
1	How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?. European Urology Oncology, 2022, 5, 135-137.	5.4	11
2	Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models. Cancer Gene Therapy, 2022, 29, 793-802.	4.6	7
3	Liquid biopsy in bladder cancer: State of the art and future perspectives. Critical Reviews in Oncology/Hematology, 2022, 170, 103577.	4.4	49
4	Delivery of antisense oligonucleotides for splice-site correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides. Prostate, 2022, 82, 657-665.	2.3	7
5	First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.. Journal of Clinical Oncology, 2022, 40, 40-40.	1.6	0
6	Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2024357119.	7.1	5
7	MP45-04â€fSELECTMDX URINE TEST DIAGNOSE MEN WITH HIGH-GRADE PROSTATE CANCER. Journal of Urology, 2022, 207, .	0.4	0
8	Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. British Journal of Cancer, 2022, 126, 907-916.	6.4	5
9	On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5051-5051.	1.6	2
10	Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 583-589.	3.9	5
11	Impact of <scp>DNA</scp> damage repair defects and aggressive variant features on response to carboplatinâ€based chemotherapy in metastatic castrationâ€resistant prostate cancer. International Journal of Cancer, 2021, 148, 385-395.	5.1	28
12	The Identification of Small Molecule Inhibitors That Reduce Invasion and Metastasis of Aggressive Cancers. International Journal of Molecular Sciences, 2021, 22, 1688.	4.1	1
13	Predictive and prognostic biomarker identification in a large cohort of androgen receptor-positive salivary duct carcinoma patients scheduled for combined androgen blockade.. Journal of Clinical Oncology, 2021, 39, 6071-6071.	1.6	0
14	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castrationâ€resistant prostate cancer undergoing firstâ€line abiraterone acetate and prednisone treatment. Molecular Oncology, 2021, 15, 2453-2465.	4.6	9
15	Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder. Molecular Oncology, 2021, 15, 1882-1900.	4.6	5
16	Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. Prostate Cancer and Prostatic Diseases, 2021, 24, 1110-1119.	3.9	40
17	Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer. World Journal of Urology, 2021, 39, 3789-3797.	2.2	14
18	Prostate Cancer Liquid Biopsy Biomarkersâ€™ Clinical Utility in Diagnosis and Prognosis. Cancers, 2021, 13, 3373.	3.7	31

#	ARTICLE	IF	CITATIONS
19	Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade. <i>Cancers</i> , 2021, 13, 3527.	3.7	10
20	Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 721659.	2.8	3
21	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. <i>Cancers</i> , 2021, 13, 3913.	3.7	5
22	642TiP Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2021, 32, S671.	1.2	2
23	Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. <i>Cancers</i> , 2021, 13, 4660.	3.7	2
24	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 6279.	3.7	5
25	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 219-230.	3.1	36
26	Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients. <i>International Journal of Cancer</i> , 2020, 146, 3196-3206.	5.1	28
27	Improving the barrier function of damaged cultured urothelium using chondroitin sulfate. <i>Neurourology and Urodynamics</i> , 2020, 39, 558-564.	1.5	11
28	Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma. <i>Oral Oncology</i> , 2020, 110, 105018.	1.5	4
29	Pyruvate-lactate exchange and glucose uptake in human prostate cancer cell models. A study in xenografts and suspensions by hyperpolarized [1-13C]pyruvate MRS and [18F]FDG-PET. <i>NMR in Biomedicine</i> , 2020, 33, e4362.	2.8	5
30	Polyisocyanide Hydrogels as a Tunable Platform for Mammary Gland Organoid Formation. <i>Advanced Science</i> , 2020, 7, 2001797.	11.2	31
31	Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 89, 102069.	7.7	32
32	Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 3756.	3.7	4
33	Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis. <i>Cancers</i> , 2020, 12, 3790.	3.7	20
34	775P Whole blood transcriptomic profiling to predict response to immunotherapy in metastatic urothelial cancer. <i>Annals of Oncology</i> , 2020, 31, S596.	1.2	0
35	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020, 66, 842-851.	3.2	25
36	Introducing PIONEER: a project to harness big data in prostate cancer research. <i>Nature Reviews Urology</i> , 2020, 17, 351-362.	3.8	18

#	ARTICLE	IF	CITATIONS
37	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 714-729.	3.0	18
38	⁶⁸ Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics, 2020, 10, 2273-2283.	10.0	45
39	Validation of a 2-gene mRNA urine test for the detection of Ψ GG2 prostate cancer in an opportunistic screening population. Prostate, 2020, 80, 500-507.	2.3	8
40	Abstract 1413: Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective observational study. , 2020, , .		0
41	PD53-04-fTHE SELECTMDX URINARY-BIOMARKER TEST. Journal of Urology, 2020, 203, e1097-e1098.	0.4	0
42	Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer and Prostatic Diseases, 2019, 22, 101-109.	3.9	51
43	Development and characterization of salivary gland cancer organoid cultures. Annals of Oncology, 2019, 30, v472-v473.	1.2	0
44	Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis. Oncogene, 2019, 38, 3696-3709.	5.9	26
45	A four-group urine risk classifier for predicting outcomes in patients with prostate cancer. BJU International, 2019, 124, 609-620.	2.5	30
46	Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. European Journal of Cancer, 2019, 110, 62-70.	2.8	46
47	Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports. BMC Urology, 2019, 19, 124.	1.4	1
48	The importance of targeting intracrinology in prostate cancer management. World Journal of Urology, 2019, 37, 751-757.	2.2	2
49	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology, 2019, 30, e3.	1.2	16
50	Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice. Urology Practice, 2019, 6, 256-261.	0.5	5
51	Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy. Journal of Urology, 2019, 202, 256-263.	0.4	74
52	Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer.. Journal of Clinical Oncology, 2019, 37, 91-91.	1.6	1
53	MP24-04-fA 2-GENE MRNA URINE TEST FOR DETECTION OF HIGH-GRADE PROSTATE CANCER PRIOR TO INITIAL PROSTATE BIOPSY. Journal of Urology, 2019, 201, .	0.4	0
54	Abstract 349: Oncolytic reovirus variants induce direct oncolysis in human prostate cancer. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 349: Oncolytic reovirus variants induce direct oncolysis in human prostate cancer. , 2019, , .		0
56	Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. Prostate, 2018, 78, 336-342.	2.3	41
57	MP46-11 EVALUATION OF TWO URINARY RNA BIOMARKER TESTS WITH AN EPIGENETIC DNA ASSAY FOR THE IDENTIFICATION OF MEN WITH HIGH-GRADE PROSTATE CANCER. Journal of Urology, 2018, 199, .	0.4	0
58	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. Therapeutic Drug Monitoring, 2018, 40, 222-229.	2.0	11
59	Genomic Markers in Prostate Cancer Decision Making. European Urology, 2018, 73, 572-582.	1.9	201
60	Long non-coding RNAs as prognostic biomarkers for castration-resistant prostate cancer. European Urology Supplements, 2018, 17, e2537.	0.1	0
61	In-depth assessment of metastatic prostate cancer with high tumour mutational burden. Annals of Oncology, 2018, 29, viii274.	1.2	3
62	Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma. Annals of Oncology, 2018, 29, viii385.	1.2	0
63	68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma and salivary duct carcinoma. Annals of Oncology, 2018, 29, viii481.	1.2	0
64	Combining multi-parametric M.R.I and an epigenetic biomarker assay improves patient prostate cancer risk profile. European Urology Supplements, 2018, 17, e2476.	0.1	0
65	Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708.	10.7	90
66	MP46-20 COST-EFFECTIVENESS OF SELECTMDX FOR PROSTATE CANCER IN FOUR EUROPEAN COUNTRIES: A MODELLING STUDY. Journal of Urology, 2018, 199, .	0.4	0
67	Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clinical Epigenetics, 2018, 10, 71.	4.1	39
68	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5036-5036.	1.6	2
69	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, 248-248.	1.6	5
70	Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy. BJU International, 2017, 119, 74-81.	2.5	17
71	Biomarkers for Prostate Cancer. , 2017, , 77-96.		0
72	Urothelium update: how the bladder mucosa measures bladder filling. Acta Physiologica, 2017, 220, 201-217.	3.8	24

#	ARTICLE	IF	CITATIONS
73	miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting <i>ADAM9</i> and <i>TGFB2</i> . Cancer Research, 2017, 77, 2008-2017.	0.9	55
74	Molecular biomarkers to guide precision medicine in localized prostate cancer. Expert Review of Molecular Diagnostics, 2017, 17, 791-804.	3.1	20
75	Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. Biomedical Chromatography, 2017, 31, e3986.	1.7	20
76	Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics – a decision analytical model. BJU International, 2017, 120, 659-665.	2.5	45
77	Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer and Prostatic Diseases, 2017, 20, 12-19.	3.9	102
78	A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. Prostate, 2017, 77, 1401-1407.	2.3	61
79	MP33-17 POTENTIAL ROLE OF A NOVEL URINARY BIOMARKER-BASED RISK SCORE TO SELECT PATIENTS FOR MULTIPARAMETRIC MRI FOR PROSTATE CANCER DETECTION.. Journal of Urology, 2017, 197, .	0.4	0
80	Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations. Stem Cell Research and Therapy, 2017, 8, 95.	5.5	14
81	Analytical validation of an mRNA-based urine test to predict the presence of high-grade prostate cancer. Translational Medicine Communications, 2017, 2, .	1.4	6
82	Overexpression of the c-MET proto-oncogene in salivary duct carcinoma patients. Annals of Oncology, 2017, 28, v374.	1.2	2
83	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget, 2017, 8, 50804-50813.	1.8	29
84	Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma. Annals of Oncology, 2017, 28, v373-v374.	1.2	0
85	A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate. Oncotarget, 2017, 8, 10565-10579.	1.8	26
86	MP53-04 IDENTIFICATION OF HIGH-GRADE PROSTATE CANCER USING URINE-BASED MOLECULAR BIOMARKERS COMBINED WITH CLINICAL RISK FACTORS. Journal of Urology, 2016, 195, .	0.4	0
87	MP02-02 MULTICENTER VALIDATION STUDY OF A MOLECULAR URINE TEST TO PREDICT HIGH-GRADE PROSTATE CANCER.. Journal of Urology, 2016, 195, .	0.4	0
88	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. Clinical Pharmacokinetics, 2016, 55, 1369-1380.	3.5	74
89	Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. European Urology, 2016, 70, 740-748.	1.9	292
90	Major milestones in translational oncology. BMC Medicine, 2016, 14, 110.	5.5	15

#	ARTICLE	IF	CITATIONS
91	TRPV4 mediates afferent pathways in the urinary bladder. A spinal c-fos study showing TRPV1 related adaptations in the TRPV4 knockout mouse. Pflugers Archiv European Journal of Physiology, 2016, 468, 1741-1749.	2.8	8
92	Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU International, 2016, 117, 215-225.	2.5	94
93	A five-gene expression signature to predict progression in T1G3 bladder cancer. European Journal of Cancer, 2016, 64, 127-136.	2.8	67
94	Urine biomarker profiling contains structure and predicts prostate cancer hormone therapy relapse. European Journal of Cancer, 2016, 61, S204.	2.8	0
95	<scp>TRPV</scp>4 channels in the human urogenital tract play a role in cell junction formation and epithelial barrier. Acta Physiologica, 2016, 218, 38-48.	3.8	22
96	Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. Clinical Chemistry and Laboratory Medicine, 2016, 54, 483-492.	2.3	47
97	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. Journal of Clinical Oncology, 2016, 34, 330-330.	1.6	1
98	XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice. PLoS ONE, 2016, 11, e0159531.	2.5	17
99	Elevated HOXC6/DLX1 mRNA biomarker levels in urine to help select patients at increased risk for high-grade prostate cancer detection upon prostate biopsy.. Journal of Clinical Oncology, 2016, 34, 31-31.	1.6	1
100	Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. Journal of Clinical Oncology, 2016, 34, 329-329.	1.6	0
101	Abstract 3768: Targeting of epithelial-to-mesenchyme transition by a novel small molecule inhibitor attenuates prostate and breast cancer invasiveness and bone metastases. , 2016, , .		0
102	The role of HOXC6 in prostate cancer development. Prostate, 2015, 75, 1868-1876.	2.3	43
103	Contemporary approaches to prostate cancer management. Future Oncology, 2015, 11, 2735-2736.	2.4	0
104	Direct dynamic measurement of intracellular and extracellular lactate in small-volume cell suspensions with ¹³C hyperpolarised NMR. NMR in Biomedicine, 2015, 28, 1040-1048.	2.8	14
105	Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clinical Cancer Research, 2015, 21, 3061-3070.	7.0	193
106	The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer. European Urology Focus, 2015, 1, 99-108.	3.1	8
107	Inflammation in the Pathophysiology of Benign Prostatic Hypertrophy. European Urology Supplements, 2015, 14, e1455-e1458.	0.1	12
108	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology, 2015, 26, 1589-1604.	1.2	279

#	ARTICLE	IF	CITATIONS
109	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 202.e19-202.e28.	1.6	8
110	Genomic Predictors of Outcome in Prostate Cancer. European Urology, 2015, 68, 1033-1044.	1.9	166
111	Involvement of orphan nuclear receptor COUP-TFII in cadherin-6 and cadherin-11 regulation: Implications in development and cancer. Mechanisms of Development, 2015, 136, 64-72.	1.7	13
112	The need for a personalized approach for prostate cancer management. BMC Medicine, 2015, 13, 109.	5.5	5
113	Dutasteride and Enzalutamide Synergistically Suppress Prostate Tumor Cell Proliferation. Journal of Urology, 2015, 193, 1023-1029.	0.4	15
114	An Update of the Interstitial Cell Compartment in the Normal Human Bladder. BioMed Research International, 2014, 2014, 1-9.	1.9	6
115	Noncoding RNAs as Novel Biomarkers in Prostate Cancer. BioMed Research International, 2014, 2014, 1-17.	1.9	83
116	Alterations of the Myovesical Plexus of the Human Overactive Detrusor. BioMed Research International, 2014, 2014, 1-8.	1.9	3
117	Evaluation of urinary prostate cancer antigen-3 (<scp>PCA</scp>3) and <i><scp>TMPRSS</scp>2</i><scp>ERG</scp></i> score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. BJU International, 2014, 114, 608-616.	2.5	22
118	Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. Prostate International, 2014, 2, 105-113.	2.3	27
119	MP31-13 THE EXPRESSION AND FUNCTION OF FAM110A IN HUMAN PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.4	0
120	Prostate Cancer Biomarker Profiles in Urinary Sediments and Exosomes. Journal of Urology, 2014, 191, 1132-1138.	0.4	95
121	Clinical use of novel urine and blood based prostate cancer biomarkers: A review. Clinical Biochemistry, 2014, 47, 889-896.	1.9	104
122	Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer. European Urology, 2014, 65, 534-542.	1.9	306
123	Self-reported acne is not associated with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 941-945.	1.6	3
124	KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. Prostate, 2014, 74, 1222-1230.	2.3	28
125	Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. Therapeutic Advances in Urology, 2014, 6, 245-252.	2.0	14
126	Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492.	10.7	372

#	ARTICLE	IF	CITATIONS
127	Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. <i>Prostate</i> , 2013, 73, 113-120.	2.3	47
128	Next Generation Screening Tests. , 2013, , 347-354.		0
129	Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. <i>European Urology</i> , 2013, 63, 201-209.	1.9	114
130	MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. <i>Oncogene</i> , 2013, 32, 277-285.	5.9	198
131	The Long and Winding Road to FDA Approval of a Novel Prostate Cancer Test: Our Story. <i>Clinical Chemistry</i> , 2013, 59, 32-34.	3.2	26
132	A New, Straightforward Ex Vivo Organoid Bladder Mucosal Model for Preclinical Research. <i>Journal of Urology</i> , 2013, 190, 341-349.	0.4	8
133	312 CAIX AND MCT4 SUPPRESSION DOWN-REGULATE THE CELL VIABILITY IN CLEAR CELL RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
134	Urinary biomarkers for prostate cancer: a review. <i>Asian Journal of Andrology</i> , 2013, 15, 333-339.	1.6	74
135	Recurrent Gene Fusions in Prostate Cancer: Their Clinical Implications and Uses. <i>Current Urology Reports</i> , 2013, 14, 214-222.	2.2	25
136	The Distribution and Function of Chondroitin Sulfate and Other Sulfated Glycosaminoglycans in the Human Bladder and Their Contribution to the Protective Bladder Barrier. <i>Journal of Urology</i> , 2013, 189, 336-342.	0.4	58
137	Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI. <i>International Journal of Molecular Sciences</i> , 2013, 14, 11347-11355.	4.1	25
138	Prostate cancer susceptibility genes on 8p21â€“23 in a Dutch population. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 248-253.	3.9	7
139	High-resolutionERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer. <i>BJU International</i> , 2013, 111, 836-842.	2.5	9
140	Molecular Identification of the Indolent Versus Lethal Tumor. , 2013, , 81-94.		0
141	An integrated framework of personalized medicine: from individual genomes to participatory health care. <i>Croatian Medical Journal</i> , 2012, 53, 301-303.	0.7	25
142	Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back. <i>Advances in Urology</i> , 2012, 2012, 1-2.	1.3	0
143	Personalized Management in Low-Risk Prostate Cancer: The Role of Biomarkers. <i>Prostate Cancer</i> , 2012, 2012, 1-7.	0.6	9
144	PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer. <i>Journal of Immunotherapy</i> , 2012, 35, 169-178.	2.4	269

#	ARTICLE	IF	CITATIONS
145	The Role of Genetic Markers in the Management of Prostate Cancer. European Urology, 2012, 62, 577-587.	1.9	92
146	Molecular Diagnosis of Prostate Cancer: <i>PCA3</i> and <i>TMPRSS2:ERG</i> Gene Fusion. Journal of Urology, 2012, 187, 795-801.	0.4	119
147	226 THE RATIONALE OF COMBINATION THERAPY TARGETING INTRATUMORAL STEROIDOGENESIS IN CASTRATION RESISTANT PROSTATE CANCER (CRPC). Journal of Urology, 2012, 187, .	0.4	0
148	257 TRPV4 IS INVOLVED IN CELL JUNCTION FORMATION IN THE UROGENITAL TRACT. AN ULTRASTRUCTURAL STUDY. Journal of Urology, 2012, 187, .	0.4	0
149	824 SULPHATED GLYCOSAMINOGLYCANS (GAG'S) CONTRIBUTE TO THE BLADDER BARRIER. Journal of Urology, 2012, 187, .	0.4	0
150	1216 DEVELOPMENT OF NOVEL PCA3 CUT-OFFS FOR INITIAL AND REPEAT BIOPSY USING DIFFERENT STATISTICAL APPROACHES WITHIN A US- EUROPEAN MULTI INSTITUTIONAL COHORT. Journal of Urology, 2012, 187, .	0.4	0
151	1210 BIOPSY-SPECIFIC PCA3- BASED PROSTATE BIOPSY NOMOGRAMS ARE HIGHLY ACCURATE. Journal of Urology, 2012, 187, .	0.4	0
152	2104 PROSPECTIVE MULTICENTER EVALUATION OF PCA3 AND TMPRSS2-ERG GENE FUSIONS AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR PROSTATE CANCER. Journal of Urology, 2012, 187, .	0.4	2
153	Aldo-keto Reductase Family 1 Member C3 (AKR1C3) Is a Biomarker and Therapeutic Target for Castration-Resistant Prostate Cancer. Molecular Medicine, 2012, 18, 1449-1455.	4.4	70
154	Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. Prostate, 2012, 72, 789-802.	2.3	30
155	DCâ€ŚSCRIPT: AR and VDR regulator lost upon transformation of prostate epithelial cells. Prostate, 2012, 72, 1708-1717.	2.3	17
156	Tubulin Tyrosine Ligase Like 12, a TTL Family Member with SET- and TTL-Like Domains and Roles in Histone and Tubulin Modifications and Mitosis. PLoS ONE, 2012, 7, e51258.	2.5	24
157	Review articles How accurate is our prediction of biopsy outcome? PCA3-based nomograms in personalized diagnosis of prostate cancer. Central European Journal of Urology, 2012, 65, 110-112.	0.3	4
158	Biomarkers for Prostate Cancer. , 2012, , 55-68.		0
159	Abstract 1112: Identification of microRNA-based therapeutic candidates using a unique lentiviral microRNA overexpression library. , 2012, , .		0
160	1616 RATIONAL BASIS FOR THE COMBINATION OF PCA3 AND TMPRSS2:ERG GENE FUSION IN PROSTATE CANCER DIAGNOSIS. Journal of Urology, 2011, 185, .	0.4	0
161	2320 INITIAL AND REPEAT PROSTATE BIOPSY: COMPARATIVE PERFORMANCE ANALYSIS OF PSA, %FPSA, PROSTATE VOLUME AND URINARY PCA3 INCLUDING DEVELOPMENT OF NOVEL PCA3 CUT-OFF THRESHOLDS. Journal of Urology, 2011, 185, .	0.4	0
162	987 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON SCORE â‰¥ 7) AT BIOPSY. Journal of Urology, 2011, 185, .	0.4	0

#	ARTICLE	IF	CITATIONS
163	1573 EXPRESSION PROFILING OF INFLAMMATION RELATED GENES IN BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2011, 185, .	0.4	0
164	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nature Genetics, 2011, 43, 1098-1103.	21.4	251
165	1907 CORRELATION OF PCA3 AND MRI WITH BIOPSY OUTCOME. Journal of Urology, 2011, 185, .	0.4	0
166	Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer. American Journal of Pathology, 2011, 178, 525-536.	3.8	102
167	Adherence Junctions and Cadherin-11 in Normal and Overactive Human Detrusor Smooth Muscle Cells. Journal of Urology, 2011, 185, 1946-1951.	0.4	1
168	The Mechanoreceptor TRPV4 is Localized in Adherence Junctions of the Human Bladder Urothelium: A Morphological Study. Journal of Urology, 2011, 186, 1121-1127.	0.4	89
169	Steroidogenic Enzymes and Stem Cell Markers Are Upregulated during Androgen Deprivation in Prostate Cancer. Molecular Medicine, 2011, 17, 657-664.	4.4	102
170	Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant. European Journal of Human Genetics, 2011, 19, 118-120.	2.8	41
171	Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer. European Urology, 2011, 60, 1045-1054.	1.9	148
172	Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in dutch prostate cancer patients. Prostate, 2011, 71, 415-420.	2.3	44
173	Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate, 2011, 71, 1701-1709.	2.3	23
174	Stem Cell Characteristics in Prostate Cancer Cell Lines. European Urology, 2010, 57, 246-255.	1.9	104
175	Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659-68. European Urology, 2010, 57, e2-e3.	1.9	6
176	Reply to Tomasz Drewa's Letter to the Editor re: Minja J. Pfeiffer, Jack A. Schalken. Stem Cell Characteristics in Prostate Cancer Cell Lines. Eur Urol 2010;57:246-55. European Urology, 2010, 57, e27.	1.9	0
177	Testosterone Measurement in Patients with Prostate Cancer. European Urology, 2010, 58, 65-74.	1.9	41
178	Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy. International Journal of Cancer, 2010, 127, 2542-2553.	5.1	35
179	Predictive value of PCA3 in urinary sediments in determining clinicopathological characteristics of prostate cancer. Prostate, 2010, 70, 10-16.	2.3	144
180	Differential expression of <i>PCA3</i> and its overlapping <i>PRUNE2</i> transcript in prostate cancer. Prostate, 2010, 70, 70-78.	2.3	47

#	ARTICLE	IF	CITATIONS
181	An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. <i>Prostate</i> , 2010, 70, 1524-1532.	2.3	18
182	The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does freeâ€toâ€total prostateâ€specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?. <i>BJU International</i> , 2010, 106, 1143-1147.	2.5	57
183	TRANSMEMBRANE PROTEASE SERINE 2 IN PROSTATE CANCER. <i>BJU International</i> , 2010, 105, 1490-1492.	2.5	3
184	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. <i>Science Translational Medicine</i> , 2010, 2, 62ra92.	12.4	140
185	The Role of PCA3 Testing in Patients with a Raised Prostate-Specific Antigen Level After Greenlight Photoselective Vaporization of the Prostate. <i>Journal of Endourology</i> , 2010, 24, 1821-1824.	2.1	10
186	PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis. <i>Cancers</i> , 2010, 2, 1432-1440.	3.7	13
187	198 TRPV4 IN STRETCH SENSATION. TRPV4 IN THE UROTHELIUM OF HUMAN BLADDER, KIDNEY & URETER COLOCALIZES WITH ADHERENCE JUNCTIONS. <i>Journal of Urology</i> , 2010, 183, .	0.4	0
188	2124 PREDICTING PROSTATE BIOPSY OUTCOME IN A SCREENING SETTING. PSA, PCA3, A KALLIKREIN PANEL, THE RISKCALCULATOR OR A COMBINATION? ERSPC ROTTERDAM. <i>Journal of Urology</i> , 2010, 183, .	0.4	0
189	1036 THE UROTHELIAL CELL-LINE RT4 EXPRESSES A GLYCOSAMINOGLYCAN (GAG) LAYER ON ITS OUTER SURFACE; AN IN VITRO MODEL FOR THE BLADDER GAG-LAYER. <i>Journal of Urology</i> , 2010, 183, .	0.4	1
190	Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. <i>European Urology Supplements</i> , 2010, 9, 675-691.	0.1	19
191	Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 241-246.	3.9	24
192	Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. <i>Carcinogenesis</i> , 2009, 30, 698-705.	2.8	68
193	Editorial Comment on: Mutations in the AXIN1 Gene in Advanced Prostate Cancer. <i>European Urology</i> , 2009, 56, 494.	1.9	1
194	Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>European Urology</i> , 2009, 56, 659-668.	1.9	161
195	ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. <i>European Urology</i> , 2009, 56, 275-286.	1.9	332
196	Preliminary evaluation of the effect of dutasteride on PCA3 in postâ€DRE urine sediments: A randomized, openâ€label, parallelâ€group pilot study. <i>Prostate</i> , 2009, 69, 1624-1634.	2.3	20
197	In vitro propagation and characterization of neoplastic stem/progenitorâ€like cells from human prostate cancer tissue. <i>Prostate</i> , 2009, 69, 1683-1693.	2.3	85
198	Reply to the letter to the editor: â€Differential expression of <i>PCA3</i> and <i>BMCC1</i> in Prostate Cancer,â€by Lavin M.F., Clarke R. and R.A. Gardiner. <i>Prostate</i> , 2009, 69, 1715-1715.	2.3	0

#	ARTICLE	IF	CITATIONS
199	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. <i>Nature Genetics</i> , 2009, 41, 221-227.	21.4	572
200	The use of PCA3 in the diagnosis of prostate cancer. <i>Nature Reviews Urology</i> , 2009, 6, 255-261.	3.8	198
201	Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time. <i>European Urology Supplements</i> , 2009, 8, 97-102.	0.1	3
202	FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST. <i>Journal of Urology</i> , 2009, 181, 814-814.	0.4	0
203	PCA3. , 2009, , 233-241.		1
204	New targets for molecular diagnosis of prostate cancer: beyond the era of PSA. <i>Central European Journal of Urology</i> , 2009, 62, 145-149.	0.3	1
205	Carotenoid and vitamin intake, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. <i>Cancer Causes and Control</i> , 2008, 19, 125-134.	1.8	25
206	Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. <i>Prostate</i> , 2008, 68, 1215-1222.	2.3	79
207	Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. <i>BJU International</i> , 2008, 102, 177-182.	2.5	19
208	Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy. <i>European Urology</i> , 2008, 54, 1081-1088.	1.9	394
209	Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. <i>European Urology</i> , 2008, 54, 1438-1439.	1.9	2
210	Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. <i>European Urology Supplements</i> , 2008, 7, 460-476.	0.1	4
211	A NEW MARKER FOR INTERSTITIAL CELLS IN THE HUMAN BLADDER. <i>Journal of Urology</i> , 2008, 179, 538-538.	0.4	0
212	PROSTATE CANCER 3 (PCA3) REPRESENTS A CLINICALLY MEANINGFUL PREDICTOR OF PROSTATE CANCER AT REPEAT BIOPSY. <i>Journal of Urology</i> , 2008, 179, 724-725.	0.4	0
213	DETECTION OF TMPRSS2-ERG FUSION TRANSCRIPTS AND PCA3 IN URINARY SEDIMENTS MAY IMPROVE DIAGNOSIS OF PROSTATE CANCER. <i>Journal of Urology</i> , 2008, 179, 685-685.	0.4	1
214	PERFORMANCE ANALYSIS OF DIFFERENT PCA3 CUT-OFFS. <i>Journal of Urology</i> , 2008, 179, 705-705.	0.4	2
215	IMPROVED PREDICTION OF PROSTATE BIOPSY OUTCOME USING PCA3, TMPRSS2:ERG GENE FUSIONS AND SERUM PSA. <i>Journal of Urology</i> , 2008, 179, 725-725.	0.4	3
216	Alcohol Consumption and Mutations or Promoter Hypermethylation of the von Hippel-Lindau Gene in Renal Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3543-3550.	2.5	9

#	ARTICLE	IF	CITATIONS
217	The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance. <i>Clinical Cancer Research</i> , 2007, 13, 939-943.	7.0	176
218	Molecular markers for prostate cancer. <i>Cancer Letters</i> , 2007, 249, 5-13.	7.2	46
219	Prostate (Cancer) Stem Cells. , 2007, , 63-72.		1
220	Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5103-5108.	7.0	312
221	Prognostic Value of p53 for High Risk Superficial Bladder Cancer With Long-Term Followup. <i>Journal of Urology</i> , 2007, 177, 80-83.	0.4	36
222	Molecular PCA3 diagnostics on prostatic fluid. <i>Prostate</i> , 2007, 67, 881-887.	2.3	49
223	The prognostic value of E-cadherin and the cadherin-associated molecules β -catenin and p120 ^{cas} in prostate cancer specific survival: A long-term follow-up study. <i>Prostate</i> , 2007, 67, 1432-1438.	2.3	54
224	Molecular aspects of hormone-independent prostate cancer. <i>BJU International</i> , 2007, 100, 52-55.	2.5	10
225	The prognostic value of E-cadherin, β -catenin and β -catenin in bladder cancer patients who underwent radical cystectomy. <i>International Journal of Urology</i> , 2007, 14, 789-794.	1.0	21
226	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , 2007, 8, 84.	2.8	39
227	Human Papilloma Virus DNA and p53 Mutation Analysis on Bladder Washes in Relation to Clinical Outcome of Bladder Cancer. <i>European Urology</i> , 2007, 52, 464-469.	1.9	39
228	Cadherin-11 is Expressed in Detrusor Smooth Muscle Cells and Myofibroblasts of Normal Human Bladder. <i>European Urology</i> , 2007, 52, 1213-1222.	1.9	41
229	Editorial Comment on: Increased Expression of Tumor-Associated Trypsin Inhibitor, TATI, in Prostate Cancer and in Androgen-Independent 22Rv1 Cells. <i>European Urology</i> , 2007, 52, 1679.	1.9	1
230	TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming. <i>Cancer Research</i> , 2006, 66, 10242-10246.	0.9	209
231	New Developments in the Pathobiology of Prostate Disease. <i>European Urology Supplements</i> , 2006, 5, 729-736.	0.1	3
232	Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. <i>European Journal of Cancer</i> , 2006, 42, 3219-3227.	2.8	22
233	Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. <i>BJU International</i> , 2006, 97, 852-855.	2.5	13
234	Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. <i>British Journal of Cancer</i> , 2006, 95, 374-377.	6.4	22

#	ARTICLE	IF	CITATIONS
235	The Prognostic Value of E-Cadherin, β -catenin, and β -Catenin in Urothelial Cancer of the Upper Urinary Tract. European Urology, 2006, 49, 839-845.	1.9	32
236	The Predictive Value of p53, p27Kip1, and β -Catenin for Progression in Superficial Bladder Carcinoma. European Urology, 2006, 50, 76-82.	1.9	21
237	Quantitative Cytology on Bladder Wash versus Voided Urine: A Comparison of Results. European Urology, 2006, 49, 1044-1050.	1.9	5
238	hTERT-Immortalized Prostate Epithelial and Stromal-Derived Cells: an Authentic In vitro Model for Differentiation and Carcinogenesis. Cancer Research, 2006, 66, 3531-3540.	0.9	90
239	Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study. Journal of Hypertension, 2005, 23, 1997-2004.	0.5	27
240	Validation of molecular targets in prostate cancer. BJU International, 2005, 96, 23-29.	2.5	14
241	Innovations in Serum and Urine Markers in Prostate Cancer. European Urology, 2005, 48, 1031-1041.	1.9	48
242	Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort study. BMC Cancer, 2005, 5, 57.	2.6	94
243	Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors. Genes Chromosomes and Cancer, 2005, 43, 273-283.	2.8	9
244	CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. International Journal of Cancer, 2005, 116, 282-284.	5.1	7
245	Molecular prostate cancer pathology: Current issues and achievements. Scandinavian Journal of Urology and Nephrology, 2005, 39, 82-93.	1.4	17
246	Androgen Receptor Mediated Growth of Prostate (Cancer). European Urology Supplements, 2005, 4, 4-11.	0.1	9
247	Molecular Diagnostics in Prostate Cancer. EAU Update Series, 2005, 3, 200-213.	0.5	12
248	EFFECT OF HYPERTHERMIA ON THE CYTOTOXICITY OF 4 CHEMOTHERAPEUTIC AGENTS CURRENTLY USED FOR THE TREATMENT OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER: AN IN VITRO STUDY. Journal of Urology, 2005, 173, 1375-1380.	0.4	92
249	Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology, 2005, 66, 35-63.	1.0	398
250	Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology, 2005, 66, 64-74.	1.0	158
251	Role of complex cadherins in cell-cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines. Oncology Reports, 2004, 11, 357.	2.6	11
252	Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Review of Molecular Diagnostics, 2004, 4, 513-526.	3.1	47

#	ARTICLE	IF	CITATIONS
253	Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. BJU International, 2004, 93, 5-9.	2.5	21
254	Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU International, 2004, 93, 27-29.	2.5	37
255	Strict regulation of CAIXG250/MN by HIF-1 α in clear cell renal cell carcinoma. Oncogene, 2004, 23, 5624-5631.	5.9	177
256	Future opportunities for the diagnosis and treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2004, 7, S8-S13.	3.9	11
257	Intravesical Gemcitabine: A Phase 1 and Pharmacokinetic Study. European Urology, 2004, 45, 182-186.	1.9	42
258	Engineered FGF-2 Expression Induces Glandular Epithelial Hyperplasia in the Murine Prostatic Dorsal Lobe. European Urology, 2004, 46, 126-132.	1.9	18
259	The Effect of Hyperthermia on Mitomycin-C Induced Cytotoxicity in Four Human Bladder Cancer Cell Lines. European Urology, 2004, 46, 670-674.	1.9	40
260	A rabbit model to tissue engineer the bladder. Biomaterials, 2004, 25, 1657-1661.	11.4	62
261	Site-specific familial aggregation of prostate cancer. International Journal of Cancer, 2004, 109, 611-617.	5.1	25
262	Translational research approaches in studying lower urinary tract symptoms: current and future challenges. Urology, 2004, 63, 1-2.	1.0	1
263	Etiology and management of pelvic pain syndrome. Urology, 2004, 63, 74.	1.0	1
264	DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer. European Urology, 2003, 44, 8-16.	1.9	603
265	Rabbit Urethra Replacement with a Defined Biomatrix or Small Intestinal Submucosa. European Urology, 2003, 44, 266-271.	1.9	45
266	Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Pigs. European Urology, 2003, 44, 615-619.	1.9	12
267	Epithelial cell differentiation in the human prostate epithelium: Implications for the pathogenesis and therapy of prostate cancer. Critical Reviews in Oncology/Hematology, 2003, 46, 3-10.	4.4	81
268	Allelic imbalance in hereditary and sporadic prostate cancer. Prostate, 2003, 54, 50-57.	2.3	12
269	Intermediate Cells in Human Prostate Epithelium Are Enriched in Proliferative Inflammatory Atrophy. American Journal of Pathology, 2003, 162, 1529-1537.	3.8	163
270	Introduction: prostate cancer: from basic science to clinical application?. Urology, 2003, 62, 1-2.	1.0	44

#	ARTICLE	IF	CITATIONS
271	Cellular and molecular biology of the prostate: stem cell biology. Urology, 2003, 62, 11-20.	1.0	134
272	New targets for therapy in prostate cancer: differential display code 3 (DD3PCA3), a highly prostate cancer-specific gene. Urology, 2003, 62, 34-43.	1.0	133
273	The Androgen Cascade in Ageing Men: Blessing or Curse?. European Urology Supplements, 2003, 2, 8-12.	0.1	11
274	The transcription factor Net regulates the angiogenic switch. Genes and Development, 2003, 17, 2283-2297.	5.9	63
275	Activated Leukocyte Cell Adhesion Molecule (ALCAM) Expression is Associated with a Poor Prognosis for Bladder Cancer Patients. UroOncology, 2003, 3, 121-129.	0.1	19
276	Cell Adhesion Molecules in Genitourinary Cancer. , 2003, , 455-472.		0
277	Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Research, 2003, 23, 3327-31.	1.1	43
278	Treatment options in hormone resistant prostate cancer. Annals of Oncology, 2002, 13, 95-102.	1.2	6
279	Analysis of expression of chorionic gonadotrophin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR. Journal of Endocrinology, 2002, 172, 489-495.	2.6	18
280	Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies. Urology, 2002, 60, 357-362.	1.0	9
281	Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. Molecular and Cellular Endocrinology, 2002, 197, 153-165.	3.2	34
282	Canine prostate carcinoma: epidemiological evidence of an increased risk in castrated dogs. Molecular and Cellular Endocrinology, 2002, 197, 251-255.	3.2	167
283	IS INCREASED CAG REPEAT LENGTH IN THE ANDROGEN RECEPTOR GENE A RISK FACTOR FOR MALE SUBFERTILITY?. Journal of Urology, 2002, 167, 621-623.	0.4	43
284	Tenascin Expression in Normal, Hyperplastic, Dysplastic and Neoplastic Canine Mammary Tissues. Journal of Comparative Pathology, 2002, 126, 1-8.	0.4	15
285	Single nucleotide polymorphism in the <i>E-cadherin</i> gene promoter modifies the risk of prostate cancer. International Journal of Cancer, 2002, 100, 683-685.	5.1	58
286	JC Virus Strains Indigenous to Northeastern Siberians and Canadian Inuits Are Unique But Evolutionally Related to Those Distributed Throughout Europe and Mediterranean Areas. Journal of Molecular Evolution, 2002, 55, 322-335.	1.8	37
287	Intermediate cells in normal and malignant prostate epithelium express c-MET: Implications for prostate cancer invasion. Prostate, 2002, 51, 98-107.	2.3	59
288	DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Research, 2002, 62, 2695-8.	0.9	484

#	ARTICLE	IF	CITATIONS
289	Immune response in hormonally-induced prostatic hyperplasia in the dog. <i>Veterinary Immunology and Immunopathology</i> , 2001, 78, 297-303.	1.2	17
290	Growth hormone induces tyrosyl phosphorylation of the transcription factors Stat5a and Stat5b in CMT-U335 canine mammary tumor cells. <i>Domestic Animal Endocrinology</i> , 2001, 20, 123-135.	1.6	10
291	Diagnostic efficacy of the Immunocyt test to detect superficial bladder cancer recurrence. <i>Urology</i> , 2001, 58, 367-371.	1.0	82
292	Branching Activity in the Human Prostate: A Closer Look at the Structure of Small Glandular Buds. <i>European Urology</i> , 2001, 39, 222-231.	1.9	12
293	Alcohol Dehydrogenase Type 3 (ADH3) and the Risk of Bladder Cancer. <i>European Urology</i> , 2001, 40, 509-514.	1.9	12
294	The Progression of Benign Prostatic Hyperplasia: Examining the Evidence and Determining the Risk. <i>European Urology</i> , 2001, 39, 390-399.	1.9	125
295	Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. <i>BJU International</i> , 2001, 88, 35-42.	2.5	53
296	Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. <i>Prostate</i> , 2001, 47, 14-20.	2.3	3
297	Proliferative activity and branching morphogenesis in the human prostate: A closer look at pre- and postnatal prostate growth. <i>Prostate</i> , 2001, 49, 132-139.	2.3	24
298	Expression of basal cell keratins in human prostate cancer metastases and cell lines. <i>Journal of Pathology</i> , 2001, 195, 563-570.	4.5	91
299	Superficial and metachronous invasive bladder carcinomas are clonally related. <i>International Journal of Cancer</i> , 2001, 93, 699-702.	5.1	24
300	A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters. <i>Cancer Gene Therapy</i> , 2001, 8, 927-935.	4.6	23
301	Canine Balloon and Signet-ring Cell Melanomas: a Histological and Immunohistochemical Characterization. <i>Journal of Comparative Pathology</i> , 2001, 125, 166-173.	0.4	22
302	Alterations in Expression of Cadherin–6 and E–Cadherin during Kidney Development and in Renal Cell Carcinoma. <i>European Urology</i> , 2000, 38, 331-338.	1.9	29
303	Complex cadherin expression in human prostate cancer cells. <i>International Journal of Cancer</i> , 2000, 85, 446-450.	5.1	122
304	Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. <i>Prostate</i> , 2000, 44, 40-48.	2.3	30
305	Partial sequencing and tissue distribution of the canine isoforms of steroid 5?-Reductase type I and type II. <i>Prostate</i> , 2000, 44, 233-239.	2.3	9
306	Antitumor activity of the polyamine analog N1,N11-diethylnorspermine against human prostate carcinoma cells. <i>Prostate</i> , 2000, 44, 313-321.	2.3	36

#	ARTICLE	IF	CITATIONS
307	Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. <i>International Journal of Cancer</i> , 2000, 87, 217-220.	5.1	67
308	Neural network-based digitized cell image diagnosis of bladder wash cytology. <i>Diagnostic Cytopathology</i> , 2000, 23, 171-179.	1.0	26
309	Models for studying benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 2000, 3, 28-33.	3.9	57
310	Demonstration of Intermediate Cells during Human Prostate Epithelial Differentiation In Situ and In Vitro Using Triple-Staining Confocal Scanning Microscopy. <i>Laboratory Investigation</i> , 2000, 80, 1251-1258.	3.7	150
311	Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2000, 10, 153-159.	2.0	87
312	Cadherin Switching in Human Prostate Cancer Progression. <i>Japanese Journal of Urology</i> , 2000, 91, 92.	0.1	2
313	Isolation and Characterization of the Promoter of the Human Prostate Cancer-specific DD3 Gene. <i>Journal of Biological Chemistry</i> , 2000, 275, 37496-37503.	3.4	34
314	Coordinate Recruitment of E-Cadherin and ALCAM to Cell-Cell Contacts by β -Catenin. <i>Biochemical and Biophysical Research Communications</i> , 2000, 267, 870-874.	2.1	55
315	Lower incidence of urothelial cell carcinoma due to the concept of a clonal origin. <i>European Journal of Cancer</i> , 2000, 36, 2385-2389.	2.8	7
316	Consecutive quantitative cytology in bladder cancer. <i>Urology</i> , 2000, 56, 584-588.	1.0	9
317	Presence of carcinoma in situ and high 2c-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt. <i>Urology</i> , 2000, 55, 363-367.	1.0	14
318	Complex cadherin expression in human prostate cancer cells. <i>International Journal of Cancer</i> , 2000, 85, 446.	5.1	4
319	Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. <i>Prostate</i> , 2000, 44, 40-48.	2.3	1
320	Cadherin switching in human prostate cancer progression. <i>Cancer Research</i> , 2000, 60, 3650-4.	0.9	345
321	Expression and Molecular Characterization of the Growth Hormone Receptor in Canine Mammary Tissue and Mammary Tumors. <i>Endocrinology</i> , 1999, 140, 5907-5914.	2.8	27
322	Molecular Genetics and Epidemiology of Prostate Carcinoma. <i>Endocrine Reviews</i> , 1999, 20, 22-45.	20.1	149
323	A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 1999, 2, 277-281.	3.9	15
324	Transient tenascin enhancement is an early event after androgen ablation in rat prostate. <i>Urological Research</i> , 1999, 27, 9-15.	1.5	5

#	ARTICLE	IF	CITATIONS
325	Differential regulation of human β -adrenoceptor subtypes. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 359, 439-446.	3.0	36
326	Changes in cadherin-catenin complexes in the progression of human bladder carcinoma. , 1999, 82, 70-76.		48
327	Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors. , 1999, 83, 591-595.		22
328	Molecular analysis of multifocal prostate cancer lesions. , 1999, 188, 271-277.		53
329	SELECTIVITY OF FINASTERIDE AS AN IN VIVO INHIBITOR OF 5 α -REDUCTASE ISOZYME ENZYMATIC ACTIVITY IN THE HUMAN PROSTATE. Journal of Urology, 1999, 161, 332-337.	0.4	73
330	Mammary growth hormone and tumorigenesis " lessons from the dog. Veterinary Quarterly, 1999, 21, 111-115.	6.7	33
331	Expression and Molecular Characterization of the Growth Hormone Receptor in Canine Mammary Tissue and Mammary Tumors. Endocrinology, 1999, 140, 5907-5914.	2.8	13
332	Molecular Genetics and Epidemiology of Prostate Carcinoma. , 1999, 20, 22-45.		39
333	DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Research, 1999, 59, 5975-9.	0.9	803
334	Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives. Prostate, 1998, 36, 62-73.	2.3	39
335	Identification and partial characterization of two steroid 5 α -reductase isozymes in the canine prostate. , 1998, 34, 222-230.		12
336	Identification of intermediate cell types by keratin expression in the developing human prostate. , 1998, 34, 292-301.		94
337	Automated image analysis for bladder cancer. Urological Research, 1998, 26, 1-5.	1.5	4
338	Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. BJU International, 1998, 81, 844-851.	2.5	22
339	Genetic and molecular markers in the prognosis of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 1998, 4, 139-144.	1.6	0
340	MULTIFOCAL TRANSITIONAL CELL CANCER AND p53 MUTATION ANALYSIS. Journal of Urology, 1998, 160, 124-125.	0.4	8
341	Bladder Wash Cytology, Quantitative Cytology, and the Qualitative BTA Test in Patients with Superficial Bladder Cancer. Urology, 1998, 51, 44-50.	1.0	67
342	DETECTION OF ABNORMAL E-CADHERIN EXPRESSION BY SIMULATED PROSTATE BIOPSY. Journal of Urology, 1998, 160, 1368-1372.	0.4	7

#	ARTICLE	IF	CITATIONS
343	Comparative Analysis of p53 Mutations in Bladder Washings and Histologic Specimens. American Journal of Clinical Pathology, 1998, 110, 647-652.	0.7	8
344	Urinary NMP22 TM and Karyometry in the Diagnosis and Follow-Up of Patients with Superficial Bladder Cancer. European Urology, 1998, 33, 387-391.	1.9	45
345	The Bard [®] BTA Test: Its Mode of Action, Sensitivity and Specificity, Compared to Cytology of Voided Urine, in the Diagnosis of Superficial Bladder Cancer. European Urology, 1998, 34, 99-106.	1.9	40
346	Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives. Prostate, 1998, 36, 62-73.	2.3	1
347	A Novel Immunoenzymatic Technique to Demonstrate Multiple Antigens in Cells Based on Selective Destaining of Substrate Deposits and Its Application in Characterizing the Immunophenotype of Neuroendocrine Cells in the Human Prostate Epithelium. Applied Immunohistochemistry & Molecular Morphology, 1998, 6, 69-76.	2.0	5
348	Intratatumoral nuclear morphologic heterogeneity in prostate cancer. Urology, 1997, 49, 652-657.	1.0	26
349	Molecular Cloning of an Alternative Human β -E-Catenin cDNA. Biochemical and Biophysical Research Communications, 1997, 237, 177-181.	2.1	2
350	Role of E Boxes in the Repression of E-Cadherin Expression. Biochemical and Biophysical Research Communications, 1997, 241, 453-458.	2.1	123
351	Differential expression of ferritin Heavy chain in a rat transitional cell carcinoma progression model. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1997, 1360, 39-44.	3.8	9
352	New Perspectives in the Treatment of Prostate Cancer. European Urology, 1997, 31, 20-23.	1.9	16
353	Rapid microwave-stimulated fixation of entire prostatectomy specimens. , 1997, 183, 369-375.		62
354	Suppression of invasive ability of highly metastatic rat prostate cancer by introduction of human chromosome 8. , 1997, 31, 14-20.		15
355	Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo. , 1997, 32, 196-204.		45
356	Relation between aberrant β -catenin expression and loss of E-cadherin function in prostate cancer. International Journal of Cancer, 1997, 74, 374-377.	5.1	82
357	Decreased expression of β -catenin is associated with poor prognosis of patients with localized renal cell carcinoma. , 1997, 74, 523-528.		40
358	Smoothelin Expression Characteristics: Development of a Smooth Muscle Cell in vitro System and Identification of a Vascular Variant.. Cell Structure and Function, 1997, 22, 65-72.	1.1	56
359	Conventional bladder wash cytology performed by four experts versus quantitative image analysis. Modern Pathology, 1997, 10, 976-82.	5.5	20
360	Quanticyt: Karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology, 1996, 48, 357-364.	1.0	38

#	ARTICLE	IF	CITATIONS
361	Prognostic Factors in Prostate Cancer. , 1996, , 77-85.		0
362	LOSS OF CHROMOSOME 9 IN TISSUE SECTIONS OF TRANSITIONAL CELL CARCINOMAS AS DETECTED BY INTERPHASE CYTOGENETICS. A COMPARISON WITH RFLP ANALYSIS. , 1996, 179, 169-176.		9
363	HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS. Journal of Pathology, 1996, 180, 295-299.	4.5	153
364	Homozygous deletions of p16INK4 occur frequently in bilharziasis-associated bladder cancer. , 1996, 68, 183-187.		24
365	The influence of high-energy shock waves on the development of metastases. Ultrasound in Medicine and Biology, 1996, 22, 339-344.	1.5	61
366	The role of cell adhesion molecules and proteases in tumor invasion and metastasis. World Journal of Urology, 1996, 14, 151-6.	2.2	39
367	p16 mutations/deletions are not frequent events in prostate cancer. British Journal of Cancer, 1996, 74, 120-122.	6.4	41
368	A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. British Journal of Cancer, 1996, 74, 573-578.	6.4	56
369	HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS. , 1996, 180, 295.		1
370	HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS. Journal of Pathology, 1996, 180, 295-299.	4.5	6
371	Complex cadherin expression in renal cell carcinoma. Cancer Research, 1996, 56, 3234-7.	0.9	47
372	Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Research, 1996, 56, 4154-8.	0.9	152
373	Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. Clinical Cancer Research, 1996, 2, 1055-61.	7.0	13
374	The effects of successive high-energy shock-wave tumor administration on tumor blood flow. Ultrasound in Medicine and Biology, 1995, 21, 243-248.	1.5	9
375	In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines. Prostate, 1995, 26, 275-280.	2.3	14
376	Liarozole, an antitumor drug, modulates cytokeratin expression in the dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid. Prostate, 1995, 27, 129-140.	2.3	21
377	BASIC RESEARCH. International Journal of Urology, 1995, 2, 117-121.	1.0	0
378	Molecular prognostic factors in bladder cancer. World Journal of Urology, 1994, 12, 84-8.	2.2	24

#	ARTICLE	IF	CITATIONS
379	Magnetic resonance spectroscopy detects metabolic differences between seven dunning rat prostate tumor sublines with different biological behavior. Prostate, 1994, 25, 19-28.	2.3	8
380	Effects of high energy shock waves on tumor blood flow and metabolism:31P/1H/2H nuclear magnetic resonance study. NMR in Biomedicine, 1994, 7, 319-326.	2.8	5
381	Transcriptional Regulation of the Human E-Cadherin Gene in Human Prostate Cancer Cell Lines: Characterization of the Human E-Cadherin Gene Promoter. Biochemical and Biophysical Research Communications, 1994, 203, 1284-1290.	2.1	67
382	The Genes for the Calcium-Dependent Cell Adhesion Molecules P- and E-Cadherin Are Tandemly Arranged in the Human Genome. Biochemical and Biophysical Research Communications, 1994, 203, 1291-1294.	2.1	46
383	p53 mutations have no additional prognostic value over stage in bladder cancer. British Journal of Cancer, 1994, 70, 496-500.	6.4	45
384	Antitumoral Effects of Liarozole in Androgen-Dependent and Independent R3327-Dunning Prostate Adenocarcinomas. Journal of Urology, 1994, 151, 217-222.	0.4	39
385	High Energy Shock Waves Induced Increase in the Local Concentration of Systemically Given TNF- $\hat{\alpha}$. Journal of Urology, 1994, 152, 2164-2166.	0.4	5
386	Therapeutic Applications of Monoclonal Antibodies in Combination with Cytokines in Renal Cell Carcinoma. , 1994, , 132-140.		0
387	Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Research, 1994, 54, 3929-33.	0.9	383
388	Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms. Invasion & Metastasis, 1994, 14, 71-81.	0.5	20
389	Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma. Analytical Cellular Pathology, 1994, 7, 153-70.	2.1	2
390	Prognostic value of karyometric and clinical characteristics in renal cell carcinoma quantitative assessment of tumor heterogeneity. Cancer, 1993, 72, 2667-2674.	4.1	29
391	The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma. Urological Research, 1993, 21, 413-421.	1.5	13
392	Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: Biological significance and clinical implications. Cancer and Metastasis Reviews, 1993, 12, 29-37.	5.9	81
393	Molecular cloning and characterization of the human E-cadherin cDNA. Molecular Biology Reports, 1993, 17, 123-128.	2.3	100
394	Biological effects of high energy shock waves in mouse skeletal muscle: Correlation between 31P magnetic resonance spectroscopic and microscopic alterations. Ultrasound in Medicine and Biology, 1993, 19, 399-409.	1.5	11
395	Characterization of Human Prostate Cancer, Benign Prostatic Hyperplasia and Normal Prostate by in vitro ¹ H and ³¹ P Magnetic Resonance Spectroscopy. Journal of Urology, 1993, 150, 2019-2024.	0.4	95
396	Antitumor Effects of Bacillus Calmette- Guerin in a Syngeneic Rat Bladder Tumor Model System, RBT323. Journal of Urology, 1993, 149, 179-182.	0.4	9

#	ARTICLE	IF	CITATIONS
397	Magnetic Resonance Spectroscopic Evaluation of the Effects of High-Energy Shock Waves Administered to a Human Kidney Cancer Xenograft. , 1993, , 34-39.		0
398	Antitumorale Wirkungen immuntherapeutischer Agenzien in vitro und in vivo in einem syngenem Tiermodell des Nierenzellkarzinoms. , 1993, , 62-71.		0
399	Genetische Schritte in Zusammenhang mit der Entstehung des Prostatakarzinoms. , 1993, , 151-165.		0
400	Image analysis in superficial transitional cell carcinoma of the bladder. Seminars in Urology, 1993, 11, 164-70.	0.4	6
401	Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Research, 1993, 53, 5512-6.	0.9	109
402	Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Research, 1993, 53, 3241-5.	0.9	271
403	Quantitative Light Microscopy in Urological Oncology. Journal of Urology, 1992, 148, 1-13.	0.4	54
404	Inhibition of Rat Bladder Tumor (Rbt323) Growth by Tumor Necrosis Factor Alpha and Interferon-Gamma in Vivo. Journal of Urology, 1992, 148, 458-462.	0.4	6
405	Increased expression of retroviral sequences in progressionally advanced rat prostatic tumors. Biochemical and Biophysical Research Communications, 1992, 182, 318-324.	2.1	3
406	Differential expression of vimentin in rat prostatic tumors. Biochemical and Biophysical Research Communications, 1992, 182, 1254-1259.	2.1	21
407	Identification of New Prostate Cancer Progression Markers by Differential Hybridization Analysis. European Urology, 1992, 21, 60-65.	1.9	1
408	Critical review of the models to study the biologic progression of bladder cancer. Journal of Surgical Oncology, 1992, 8, 274-278.	1.4	16
409	Karyometry in recurrent superficial transitional cell tumors of the bladder. Urological Research, 1992, 20, 375-381.	1.5	13
410	Prediction of Cytokine-Therapy on Basis of Class-I and Class-II MHC Antigen Induction. , 1992, , 121-133.		0
411	Establishment and characterization of five new human renal tumor xenografts. American Journal of Pathology, 1992, 140, 483-95.	3.8	18
412	Karyometry of bladder washings for the follow up of patients with transitional cell carcinoma of the bladder. Progress in Clinical and Biological Research, 1992, 378, 9-18.	0.2	1
413	Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Research, 1992, 52, 6182-7.	0.9	143
414	Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Research, 1992, 52, 5104-9.	0.9	450

#	ARTICLE	IF	CITATIONS
415	Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Research, 1992, 52, 2916-22.	0.9	133
416	Effects of high-energy shock waves combined with biological response modifiers in different human kidney cancer xenografts. Ultrasound in Medicine and Biology, 1991, 17, 391-399.	1.5	33
417	Early metabolic response to high energy shock waves in a human tumor kidney xenograft monitored by ³¹ P magnetic resonance spectroscopy. Ultrasound in Medicine and Biology, 1991, 17, 791-801.	1.5	19
418	Cytotoxic Effects of High Energy Shock Waves in different in Vitro Models: Influence of the Experimental Set-Up. Journal of Urology, 1991, 145, 171-175.	0.4	39
419	Androgen receptors in endocrine-therapy-resistant human prostate cancer. International Journal of Cancer, 1991, 48, 189-193.	5.1	341
420	HLA-class-I and-class-II expression on renal tumor xenografts and the relation to sensitivity for $\hat{I}\pm$ -IFN, $\hat{I}\beta$ -IFN and TNF. International Journal of Cancer, 1991, 48, 709-716.	5.1	24
421	H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection. Prostate, 1991, 18, 163-172.	2.3	30
422	Differential antiproliferative activities of alpha- and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. Prostate, 1991, 18, 331-344.	2.3	24
423	Use of animal models in diagnosis and treatment of renal cell carcinoma. World Journal of Urology, 1991, 9, 192-197.	2.2	2
424	Oncogene expression in prostate cancer. World Journal of Urology, 1991, 9, 58-63.	2.2	11
425	Image analysis and grading of prostate adenocarcinoma. World Journal of Urology, 1991, 9, 86-94.	2.2	1
426	Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations. Urological Research, 1991, 19, 91-98.	1.5	19
427	Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems. , 1991, , 47-55.		0
428	Antitumor Effects of High-Energy Shock Waves are Potentiated by Doxorubicin and Biological Response Modifiers. , 1991, , 228-237.		0
429	Cytokeratin expression patterns in metastatic transitional cell carcinoma of the urinary tract. An immunohistochemical study comparing local tumor and autologous metastases. American Journal of Pathology, 1991, 139, 1389-400.	3.8	29
430	Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Research, 1991, 51, 606-11.	0.9	88
431	In Vivo Effects of High Energy Shock Waves on Urological Tumors: An Evaluation of Treatment Modalities. Journal of Urology, 1990, 144, 785-789.	0.4	53
432	In Vivo Antiproliferative Effects of Gamma-Interferon and Tumor Necrosis Factor Alpha in a Rat Renal Cell Carcinoma Model System. Journal of Urology, 1990, 143, 1247-1251.	0.4	16

#	ARTICLE	IF	CITATIONS
433	Effects of high-energy shock waves combined with biological response modifiers or Adriamycin on a human kidney cancer xenograft. Urological Research, 1990, 18, 419-424.	1.5	22
434	Allelic loss of chromosomes 16q and 10q in human prostate cancer.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8751-8755.	7.1	436
435	Oncogene expression in prostate cancer. Progress in Clinical and Biological Research, 1990, 357, 97-105.	0.2	2
436	The in vitro effect of electromagnetically generated shock waves (Lithostar) on the Dunning R3327 PAT-2 rat prostatic cancer cell-line. Urological Research, 1989, 17, 13-19.	1.5	48
437	Intermediate filament expression and the progression of prostatic cancer as studied in the dunning R-3327 rat prostatic carcinoma system. Prostate, 1989, 14, 323-339.	2.3	25
438	In Vitro Sensitivity of Three Human Renal Tumor Xenografts Towards Tumor Necrosis Factor and Alpha and Gamma Interferon. , 1989, , 30-38.		2
439	Oncogenes and urological malignancies: Implications for the future. Urological Research, 1988, 16, 333-339.	1.5	4
440	In vitro antiproliferative efficacy of Interferon-alpha,gamma and Tumor Necrosis Factor on two human renal tumor xenografts. Urological Research, 1988, 16, 309-314.	1.5	11
441	Effect of alpha- and gamma-Interferon and tumor necrosis factor on colony formation of two human renal tumor xenografts in vitro. Journal of Surgical Oncology, 1988, 4, 195-198.	1.4	8
442	Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate, 1988, 13, 25-38.	2.3	162
443	Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. Cancer Research, 1988, 48, 2042-6.	0.9	32
444	Genetic organization of the c-sistranscription unit. Nucleic Acids Research, 1987, 15, 959-970.	14.5	24
445	Expression of Proto-Oncogenes in Xenografts of Human Renal Cell Carcinomas. Journal of Urology, 1987, 137, .	0.4	0
446	Differential Expression of Genes in Metastasizing and Non-Metastasizing Prostatic Tumor Cells. Journal of Urology, 1987, 137, .	0.4	0
447	Analysis of a cDNA clone expressing a human autoimmune antigen: full-length sequence of the U2 small nuclear RNA-associated B" antigen.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 2421-2425.	7.1	117
448	Expression of proto-oncogenes in xenografts of human renal cell carcinomas. Urological Research, 1987, 15, 349-353.	1.5	3
449	Structure of the feline c-fes/fps proto-oncogene: genesis of a retroviral oncogene. Journal of Virology, 1987, 61, 2009-2016.	3.4	34
450	fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas.. Journal of Clinical Investigation, 1987, 80, 1545-1549.	8.2	143

#	ARTICLE	IF	CITATIONS
451	Experssion of the human fes cellular oncogene in renal cell tumors. Urological Research, 1986, 14, 123-127.	1.5	13
452	Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene. Molecular Biology Reports, 1986, 11, 117-125.	2.3	96
453	Structure and nucleotide sequence of the 5' region of the human and feline c-sis proto-oncogenes. Nucleic Acids Research, 1986, 14, 765-778.	14.5	26
454	Evolutionary conserved close linkage of the c-fes/fps proto-oncogene and genetic sequences encoding a receptor-like protein. EMBO Journal, 1986, 5, 2197-202.	7.8	67
455	Molecular cloning of the feline c-fes proto-oncogene and construction of a chimeric transforming gene. Gene, 1985, 35, 33-43.	2.2	7
456	Characterization of the feline c-abl proto-oncogene. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1985, 824, 104-112.	2.4	14
457	Comparative analysis of the human and feline c-sis proto-oncogenes. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1985, 825, 140-147.	2.4	19
458	The structure of the human c-fes/fps proto-oncogene. EMBO Journal, 1985, 4, 2897-903.	7.8	49
459	Molecular alterations associated with prostate cancer development. , 0, , .		0